SENATE-BILL 2276: S.2276 - ETHIC Act
AI-Powered Summary
SENATE-BILL 2276 aims to reform patent law by imposing limitations on the number of patents that can be asserted in infringement actions, particularly impacting individuals and entities in the pharmaceutical and biotechnology sectors. The legislation seeks to enhance competition and innovation by reducing patent thickets, which may also implicate constitutional rights such as due process and the right to engage in commerce. Key provisions include the restriction of asserting only one patent per Patent Group in infringement cases, which could streamline legal proceedings and influence patent strategies moving forward. The bill's amendments will apply to new patent applications submitted after its enactment, indicating a forward-looking approach to patent law reform. Overall, the bill has the potential to reshape the landscape of patent litigation, affecting how intellectual property is protected and enforced, while balancing the interests of patent holders and the need for competitive markets.
Demographic Impact Analysis
Summary
Overall Constitutional Implications
The ETHIC Act has significant implications for individual rights, particularly in enhancing access to healthcare. By reducing barriers to generic and biosimilar drugs, it supports the right to health and promotes equity in healthcare access, especially for economically disadvantaged groups.
Key Individual Rights Affected
- Right to Access Healthcare
- Equal Protection under the Law
- Intellectual Property Rights
Constitutional Provisions
- 14th Amendment - Equal Protection Clause
- 5th Amendment - Right to Property
Potential Constitutional Challenges
While the bill supports individual rights by improving access to medications, it may face challenges from patent holders claiming infringement of their property rights under the Fifth Amendment. The balance between protecting intellectual property and promoting public health will be a critical area of legal scrutiny.
Summary
The ETHIC Act is designed to facilitate market entry for generic drugs, thereby enhancing access to affordable medications for individuals across various demographic groups. Its potential benefits are particularly pronounced for low-income individuals and families, who may struggle with the costs of prescription drugs. However, the bill also raises important questions about the balance between patent rights and public welfare, which could lead to legal challenges. Overall, the legislation is a step towards supporting individual rights related to healthcare access.
Constitutional Analysis
This bill appears to align with constitutional principles. The proposed legislation operates within the established framework of constitutional authority and does not appear to conflict with fundamental rights or the separation of powers.
Analysis generated using AI-powered review of constitutional principles and legal precedents.
Take Action
Text 50409
💡 How to use:
These links will start a conversation with ResistBot. When prompted, mention S. 2276 to reference this bill.
Contact Your Representatives
Write to YOUR elected officials about this bill
Rate This Bill
Sign in to save a private rating for this bill and track your civic engagement over time.
Sign In FreePolicy Topics
Timeline
July 15, 2025
Bill Introduced
Current
Referred to Committee
June 12, 2026
Last Updated
Ask the Constitutional AI About This Bill
Sign in free to chat with our constitutional analysis AI about this bill — get plain-English explanations, constitutional concerns, and demographic impact estimates personalized to you.
Sign In Free to Chat